News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Second Phase II Clinical Trial Confirms Safety and Efficacy Trends for Auris Medical AG's AM-101 in Treatment of Acute Peripheral Tinnitus


9/9/2013 9:27:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 9, 2013 – Second phase II clinical trial confirms safety and efficacy trends for Auris Medical’s AM-101 in treatment of acute peripheral tinnitus Auris Medical announced today positive results from the TACTT11 study, its second phase II clinical trial with AM-101 for the treatment of acute peripheral tinnitus. The study provided further evidence for the safety and efficacy of the treatment and supports the conduct of phase III confirmatory studies.

The randomized, placebo-controlled, double-blind study was conducted in the USA, Belgium, Germany and Poland. It enrolled patients suffering from tinnitus following traumatic injury to the cochlea (acute noise trauma, inner ear barotrauma, middle ear surgery) or otitis media up to 3 months after tinnitus onset. A total of 85 patients were randomized to receive AM-101 at 0.81 mg/mL or placebo by way of intratympanic injection either in a single dose (stage 1 of the trial) or in three doses over two weeks (stage 2) by way of intratympanic injection. Following treatment, study participants were observed for 90 days.

Preliminary results from the TACTT1 study show that both single and triple dose treatments with AM-101 were well tolerated. Occurrence of adverse events or clinically relevant hearing loss overall was low to moderate with no statistically significant differences between treatment groups and dose regimens. As in the previous studies with AM-101, most adverse events were mild or moderate in intensity and represented transient local effects of the injection procedure. At <0.2 ng/mL, the concentrations of AM-101’s active substance and primary metabolite in blood plasma were close to the analytical limits of quantification, thus confirming the minimal systemic exposure offered by the intratympanic approach.

In addition, the TACTT1 trial showed a clear trend for superior improvement in AM-101 treated study participants over placebo groups with regards to subjective tinnitus loudness, annoyance, sleep difficulties, tinnitus handicap/impact and tinnitus severity. Although the study was not powered to demonstrate statistical significance between treatment groups, the difference between active and placebo groups was significant for several efficacy outcomes. The results were also broadly in line with the trends observed in the previous phase II trial with AM-101. The primary endpoint, the change in tinnitus loudness from baseline to the last follow-up visit, did not show any statistically significant difference between dose regimens.

“We are very pleased with the positive outcomes from this second phase II study with AM-101,” commented Thomas Meyer, Auris Medical’s founder and Managing Director. “They corroborate and complement the promising results from our previous trials and provide strong support for our planned phase III confirmatory studies.” He added: “The almost 900 intratympanic injections that have been performed in our clinical development programme so far helped us gain valuable insights into the nature and size of treatment responses at different concentrations, under different dose regimens and for tinnitus with different origins.” These insights together with outcomes from discussions with regulatory agencies will be reflected in the design for the phase III trials which are expected to start later this year.

About acute peripheral tinnitus

Tinnitus, the perception of sound without external acoustic stimulation, is a symptom common to various ear or other diseases. Inner ear tinnitus may be provoked by various injuries to the cochlea, the organ of hearing, such as overexposure to noise or inflammation. It may be short and just transitory; however, it may also become permanent. Tinnitus of less than three months of duration is considered acute, while older tinnitus is considered chronic.

Inner ear tinnitus may be only a slight nuisance, but often it has a serious impact on the ability to sleep, relax, or concentrate, or it may lead to tiredness, irritation, nervousness, despair, frustration, or even depression. As of today, there exists neither a universal standard of care for acute inner ear tinnitus, nor a truly proven, effective treatment method.

About AM-101

AM-101 is a small molecule N-methyl-D-aspartate (NMDA) receptor antagonist formulated in a biocompatible gel for intratympanic injection. Emerging evidence suggests that NMDA receptors in the cochlea play a major role in the occurrence of tinnitus following inner ear excitotoxicity, which is characterized by excessive synaptic release of glutamate, the principal neurotransmitter in the auditory system. Cochlear excitotoxicity may be triggered by, for example, trauma (e.g. exposure to excessive noise), neuroinflammation, disturbances in inner ear blood supply (anoxia/ischemia), or the administration of certain ototoxic drugs. It has been proposed that the upregulation of NMDA receptors induced by cochlear excitotoxicity is responsible for aberrant excitation of auditory nerve fibres, which is perceived as tinnitus.

The development of AM-101 is based on research conducted at the INSERM Institute for Neurosciences of Montpellier, France. The clinical development of AM-101 was initiated by Auris Medical in 2007. Following proof of concept, confirmatory Phase III clinical trials are currently under preparation. Patents have been granted in more than 30 countries worldwide to date.

About Auris Medical

Auris Medical is a biotechnology company developing specific pharmaceutical compounds for the prevention or treatment of inner ear disorders, an area of great unmet medical need. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Basel, Switzerland.

Contact:

Dr. Thomas Meyer, Managing Director, telephone +41 61 201 13 50, tm@aurismedical.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES